One hundred and forty two patients with duodenal ulcer who after a short term study had relief of pain and healed ulcers proved endoscopically were allocated at random to double blind maintenance treatment with enprostil (a synthetic dehydroprostaglandin E2) 35 pg or ranitidine 150 mg at bedtime for up to 12 months. Patients were monitored every third month and examined by endoscopy at three, six, and 12 months, or more often if warranted. The cumulative relapse rates in the enprostil group at three, six, and 12 months were 37% (25/67), 56% (37/66), and 62% (41/66), respectively. The corresponding rates in the ranidine goup were 8% (6/71), 190/. (13/69), and 29% (20/69). These differences were highly significant and further enhanced by life table analysis adjusting for withdrawals and by an "intention to treat" analysis in which absence of proof of nonrecurrence was counted as failure, more patients in the enprostil group having been withdrawn because of adverse events or recorded as non-compliant with the protocol.
Introduction
An important challenge in the drug treatment of duodenal ulcer is the prevention of recurrence, which may be associated with pain and complications. Though prolonged use of drugs (maintenance treatment) has still not been proved to reduce the incidence of complications in the long term,' several agents have been shown to reduce the incidence of endoscopic relapse. Nevertheless, even ranitidine 150 mg taken at bedtime fails to prevent recurrence in every third3 or fourth4 patient within one year. Synthetic prostaglandin analogues of the E series offer a new approach to the prevention of relapse.' These agents are believed to maintain mucosal integrity by decreasing secretion of gastric acid and in addition by protecting the mucosa, independently of acid inhibition,"8 by a mechanism termed "cytoprotection."' Enprostil is a synthetic dehydroprostaglandin E2 which combines antisecretory's" with cytoprotective properties, such as to protect the antral mucosa against damage by aspirin even at doses below those required for acid inhibition. ' Results were subjected to both a "per protocol" analysis (that is, excluding patients non-compliant with the protocol) and an "intention to treat" analysis (that is, including all patients recruited). Per protocol analysis was done (a) by comparing the traditional crude relapse rates and (b) by comparing relapse rates computed by a life table method. The crude relapse rates-that is, the ratio between the number ofpatients who relapsed and the number recruited, less patients non-compliant with the protocol-were tested by an actuarial extension' of the Mantel-Haenszel statistics.'7 The Cutler-Ederer life table method'9 was used to obviate overstatement of the probability of no recurrence in the calculations of crude rates, which assume that patients withdrawn do not experience recurrence. The method adjusts for withdrawals in each period by assuming that the patients were at risk for half that period and that this risk was identical with that of patients in the same treatment group who were not withdrawn. The method entails five steps: (a) subtracting half of the withdrawals from the total number of evaluable patients receiving each treatment in a time interval; (b) calculating the proportion of patients with a relapse relative to this number; (c) subtracting this proportion from unity to give the interval specific proportion with no relapse; (d) multiplying this proportion and those for all preceding intervals to produce the cumulative maintenance rate; and (e) subtracting this from unity to give the cumulative relapse rate. The MantelHaenszel test'7 was applied to these results. The life table method ignores patients non-compliant with the protocol from the time of non-compliance.
Finally, the Mantel-Haenszel statistics and the actuarial method were applied on an intention to treat basis with estimation of failure (taken as absence of proof of non-recurrence) as the event of interest: (a) the proportion of patients with proved non-recurrence was determined relative to the number at risk; (b) the maintenance rate through the end of a specific interval was the product of this proportion and those for all preceding intervals; (c) for each interval the failure rate was obtained by subtracting the maintenance rate during the interval from unity. The 95% confidence limits for differences in relapse and failure rates between the treatment groups were also calculated."
Results
Between September 1984 and September 1985 all 142 of the 180 patients in the short term study'" who were eligible consented to further study-130 from centre 1 (Odense) and 12 from centre 2 (Bispebjerg). Seventy one were allocated to receive enprostil (65 from centre 1) and 71 to receive ranitidine (65 from centre 1). The treatment groups were well matched for selected patient characteristics (table I) .
During the first three months three patients in the enprostil group were withdrawn because of dizziness, diarrhoea, and pain, respectively, and four failed to comply (two had not taken the prescribed amount ofmedicine, one received ranitidine from his general practitioner, and one emigrated). In the ranitidine group one patient, who suffered epigastric pain, was also withdrawn. Endoscopy showed duodenitis but no ulcer recurrence. During months 4-6 four patients in the enprostil group were withdrawn (because of diarrhoea, fatigue, and (in two cases) epigastric pain without endoscopic evidence of ulcer recurrence) and one stopped taking the capsules. In the ranitidine group two patients were withdrawn because of diarrhoea and epigastric pain (but no ulcer), respectively, and two others were noncompliant (one failed to attend for endoscopy and one stopped the treatment). During months 7-12 one patient in the enprostil group and two in the ranitidine group were withdrawn because of epigastric pain (no ulcer recurrences were found), one patient taking enprostil was withdrawn because of diarrhoea, and one taking ranitidine wished to stop further treatment. Table II summarises outcome in the two treatment groups.
Uker relapse-Cumulative relapse rates were significantly higher in the enprostil group than in the ranitidine group at any point in the study (table  III) regardless of the method of analysis (crude rates and life table method).
In both treatment groups relapse rates were higher among smokers, but not significantly so (table IV) . The ulcer relapse was asymptomatic in 15% (6/41) of patients taking enprostil and in 10% (2/20) taking ranitidine (p>0 05). In 16 patients completed the 12 month study without relapse. Seven patients had not used antacids, two had used antacids in a single (three month) period, and seven had used antacids more regularly. Corresponding'figures in the ranitidine group were 27 of43, 10 of43, and six of 43, respectively (X2=6 1, df=2, p<005).
Unexpected symptoms and laboratoryfindings-Diarrhoea (that is, increased stool frequency or loose stools, or both) was reported by a further two patients (in addition to those mentioned above) taking enprostil, and two taking ranitidine reported transient headache. The paired t' test showed a small but significant increase in haemoglobin concentrationin the ranitidine group after the-trial. No other trends in laboratory values were found in either study group. In several cases a single value fell outside the reference range for the laboratory concerned, but such abnormalities occurred at random in both treatment groups. Discussion These findings show that ranitidine 150 mg at bedtime is superior to enprostil 35 tg at bedtime in preventing relapse of duodenal ulcer. The extreme differences in relapse rates were surprising because enprostil 35 [tg has been claimed to have antisecretory effects comparable'0 or superior" to those of cimetidine 600 mg. Relapse rates in the ranitidine group were comparable with rates reported in other recent trials.3 4By contrast, the relapse rates in the enprostil group were ofthe same magnitude as those described after placebo2 and similar to rates found in our population after treatment for duodenal ulcer healing." 21 Hence enprostil, which is also inferior to ranitidine for duodenal ulcer healing,'5 22 cannot be recommended for the prevention of ulcer relapse.
The dose of enprostil used in this study inhibits acid secretion, and the therapeutic benefit, if any, is explicable by this effect rather than by any mythical "cytoprotection" which may be achieved at lower doses.'4 These results and our previous findings in studies on duodenal ulcer healing'5 and duodenal ulcer haemorrhage23 question the clinical relevance of promoting cytoprotective properties of prostaglandin analogues for duodenal ulcer treatment.
SHORT REPORTS
Irritable bowel syndrome as a cause of chronic pain in women attending a gynaecology clinic Chronic lower abdominal pain and pelvic pain is a common problem in gynaecological practice. Most of these women undergo diagnostic laparoscopy, which shows a normal pelvis in up to 90%4/o of cases.' Despite the lack of a definite abnormality further gynaecological procedures are often undertaken, which may include surgery.
The irritable bowel syndrome is common and a recognised cause of chronic pain. It is associated with many non-colonic features, including dyspareunia,2 and is more prevalent in young women.3 A diagnosis of the irritable bowel syndrome is made on the history alone, and, although results of special investigations are by definition negative, the diagnosis should not simply be one of exclusion. 4 The purpose of this study was to see whether patients attending a gynaecological clinic with chronic pain might be suffering from the irritable bowel syndrome by taking a detailed history using Manning's questionnaire, which has been shown to identify successfully such patients.4
Patients, methods, and results
Fifty patients with chronic abdominal pain who had been shown to have no pelvic disease at laparoscopy were studied at their follow up visit. The women were aged between 18 and 35 and had had symptoms for at least three months. Each patient was asked the questions listed in the table and then examined for the physical signs. The table shows the number of positive responses to each question.
At least 26 patients admitted to looser stools at the onset of pain, pain eased by defecation, distension, mucus per rectum, hard pellet stools, or dyspareunia. Similarly, 38 patients had a tender, palpable colon and 36 rectal tenderness per vagina. Thirty patients had at least three symptoms associated with the irritable bowel syndrome and these patients were very likely to have the disorder. A further eight patients had two symptoms of the irritable bowel syndrome. Only three patients had none of these symptoms. 
Comment
The questionnaire has been shown to identify successfully those patients with the irritable bowel syndrome.4 Dyspareunia is not one of Manning's symptoms but has been shown to be associated with the syndrome.2 It is another manifestation of a tender colon. Similarly, a tender colon and rectal tenderness are associated with the syndrome. 5 The combination of chronic pain and three symptoms of the irritable bowel syndrome supported the diagnosis in 30 (60%) of the patients in this study. A further eight patients may have been suffering from the condition with two symptoms. As the irritable bowel syndrome may be present without an abnormal bowel habit3 the diagnosis was not excluded in the other 12 patients. The presence of
